News articles about Amedisys (NASDAQ:AMED) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amedisys earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the health services provider an impact score of 45.7011598626866 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Amedisys (AMED) Upgraded to Buy by Zacks Investment Research (americanbankingnews.com)
- Interesting AMED Put And Call Options For February 16th (nasdaq.com)
- Form 8-K AMEDISYS INC For: Jan 10 (streetinsider.com)
- Amedisys Inc (AMED) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
A number of research analysts have commented on AMED shares. Robert W. Baird restated a “hold” rating and set a $50.00 price target on shares of Amedisys in a research note on Wednesday, October 4th. SunTrust Banks reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research note on Monday, October 9th. Jefferies Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research note on Thursday, October 12th. Royal Bank of Canada reiterated a “hold” rating on shares of Amedisys in a research note on Monday, October 23rd. Finally, Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and increased their price objective for the company from $55.00 to $65.00 in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. Amedisys currently has an average rating of “Hold” and an average price target of $61.00.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The company had revenue of $380.20 million for the quarter, compared to analysts’ expectations of $384.59 million. During the same period last year, the firm earned $0.36 earnings per share. Amedisys’s quarterly revenue was up 5.1% on a year-over-year basis. equities research analysts predict that Amedisys will post 2.24 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Amedisys (NASDAQ:AMED) Earning Somewhat Positive News Coverage, Study Shows” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://baseballnewssource.com/markets/amedisys-amed-earning-somewhat-favorable-news-coverage-study-shows/1819511.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.